Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.43 |
| ▸ | PDE4A | P27815 | 13/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710144 | 0.95 | ALDH1A1 (0.46) | ALDH1A1HKDC1TSHRMEN1KMT2A | |
| SCHEMBL4925674 | 0.88 | ALDH1A1 (0.50) | ALDH1A1HKDC1TSHRMEN1KMT2A | |
| SCHEMBL4708792 | 0.76 | PDE4B (0.78) | ALDH1A1TSHRMEN1KMT2APDE4B | |
| SCHEMBL4924038 | 0.76 | PDE4B (0.78) | ALDH1A1MEN1KMT2APDE4BPDE4A | |
| SCHEMBL4923387 | 0.74 | PDE4B (0.80) | PDE4BPDE4APDE4D | |
| SCHEMBL4924655 | 0.73 | PDE4B (0.80) | ALDH1A1MEN1KMT2APDE4BPDE4A | |
| SCHEMBL4711537 | 0.68 | ALDH1A1 (0.59) | ALDH1A1TSHRKMT2A | |
| SCHEMBL4914577 | 0.67 | PDE4B (0.83) | ALDH1A1TSHRMEN1KMT2APDE4B | |
| SCHEMBL4927782 | 0.67 | PDE4B (0.69) | PDE4BPDE4APDE4D | |
| SCHEMBL4920419 | 0.63 | PDE4B (0.93) | PDE4BPDE4APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221096-A1 | Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221096-A1 | Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives | NR1H2, CBR3, NR4A1 | ALDH1A1 2625/4885HKDC1 2913/4885TSHR 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.